Clinical translation

Project-related publications
P1, P3, P4, Z
Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trial
Ann Hematol
2026
P1, P2, INF, Z, P3
KMT2A-rearranged B-lymphoblastic lymphomas are skewed towards a more mature developmental stage
Leukemia
2026
P1, P3, P4, P6, INF, Z
Intra-subtype heterogeneity shapes treatment response in KMT2A-rearranged ALL across all age groups
P1, P3, P4, Z, INF, P6
IDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma
P1, P3, P4, Z
NGS-based IG/TR rearrangement profiling in acute lymphoblastic leukemia: age dependence of immunogenetic maturation
P1, P3, P6, P7, Z
The IL-7R antagonist Lusvertikimab reduces leukemic burden in xenograft-ALL via antibody-dependent cellular phagocytosis
P1, P3, P4, Z, INF
Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.
P1, P3, P4, INF, Z
The Gene Expression Classifier ALLCatchR Identifies B-cell Precursor ALL Subtypes and Underlying Developmental Trajectories Across Age
P1, P3, P4, INF, Z
IGH Rearrangement Evolution in Adult KMT2Arearranged B-cell Precursor ALL: Implications for Cell-of-origin and MRD Monitoring
P3, P6, P7, Z
Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B-cell Precursor Acute Lymphoblastic Leukemia
P3, P4, P6, P7, Z
Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL
P1, P3, P4, INF, Z
UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment
P1, P3, P6, Z
CD79a promotes CNS-infiltration and leukemia engraftment in pediatric B-cell precursor acute lymphoblastic leukemia
P1, P6, P7, Z
Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia
P1, P3, P4, Z